European Medicines Agency Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Relapsed or Refractory Burkitt’s Lymphoma

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement